Nevada Democrats dropping caucus app after Iowa fiasco

LAS VEGAS — Reacting to tech troubles in Iowa, Nevada Democrats scrapped plans to use similar technology at their caucuses in less than three weeks, as early voting states sought to re-assure the public that they could pull off smooth elections. Officials in South Carolina and New Hampshire expressed confidence in their primary election systems, while Democrats in Nevada, the […]

Read more

Workday earnings and sales top expectations amid push into financial software

Workday Inc. sales grew by more than 25% in the most recent quarter, belying expectations of more moderate growth as the cloud-software company looks to supplement new offerings with acquisitions. Workday WDAY, +0.91% reported third-quarter losses of $115.7 million, or 51 cents a share, on sales of $938.1 million, up from $743 million a year ago. After adjusting for stock-based compensation […]

Read more

VMWare in talks to buy Pivotal Software; both controlled by Dell

(Reuters) – VMware Inc (VMW.N) and Pivotal Software Inc (PVTL.N) are negotiating a deal for VMWare to acquire Pivotal, according to a regulatory filing from Dell Technologies Inc (DELL.N) on Wednesday, valuing Pivotal, a maker of software development and management tools, at about $4 billion. Pivotal shares jumped 63% to $13.60, while shares of VMWare were down about 3% at […]

Read more

Snap earnings: Well, this could be a doozy of a conference call

When Snap Inc. last reported earnings, the biggest concerns were the redesign of Snapchat and a declining user base. Ah, what an innocent time. In just the first month of 2019, Snap SNAP, +0.29% experienced two controversial executive departures that have raised questions about stability at the young app company. The new, high-profile chief financial officer — Tim Stone, who was […]

Read more

UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal

Bristol-Myers Squibb Co. shares BMY, +0.92% fell 4% in premarket trade Monday, after the company said a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals. The company said the Phase 3 study called CheckMate -459 evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular […]

Read more
1 2 3 9